Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective c...
Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study
About this item
Full title
Author / Creator
Pan, Hong , Gao, Zhen , Lian, Yu , Zhao, Jingyu , Zhang, Lele , Li, Weiwang , Li, Ruonan , Liang, Qian , Xu, Jing , Li, Liyun , Yu, Xiao , Kuang, Zhexiang , Shi, Jun and Fang, Liwei
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
While Azacitidine combined with HAG (HHT, low-dose cytarabine, G-CSF) regimen has shown promise in treating older and unfit patients with acute myeloid leukemia (AML), its efficacy in younger patients remains understudied. This study evaluates the effectiveness and safety of Azacitidine combined with the HAG regimen in a broader patient cohort, inc...
Alternative Titles
Full title
Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_12031814
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_12031814
Other Identifiers
ISSN
0939-5555
E-ISSN
1432-0584
DOI
10.1007/s00277-024-06171-3
